I guess today's profit guidance update answers that question.I've added to my position today. Hard to see how you could go wrong at these prices.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
TLS Telstra to boost phone plan prices despite inflation – and despite claiming they wouldn't 2 months ago